Cargando…

An AI-driven clinical care pathway to reduce 30-day readmission for chronic obstructive pulmonary disease (COPD) patients

Healthcare regulatory agencies have mandated a reduction in 30-day hospital readmission rates and have targeted COPD as a major contributor to 30-day readmissions. We aimed to develop and validate a simple tool deploying an artificial neural network (ANN) for early identification of COPD patients wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lin, Li, Guihua, Ezeana, Chika F., Ogunti, Richard, Puppala, Mamta, He, Tiancheng, Yu, Xiaohui, Wong, Solomon S. Y., Yin, Zheng, Roberts, Aaron W., Nezamabadi, Aryan, Xu, Pingyi, Frost, Adaani, Jackson, Robert E., Wong, Stephen T. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712389/
https://www.ncbi.nlm.nih.gov/pubmed/36450795
http://dx.doi.org/10.1038/s41598-022-22434-3
_version_ 1784841775994634240
author Wang, Lin
Li, Guihua
Ezeana, Chika F.
Ogunti, Richard
Puppala, Mamta
He, Tiancheng
Yu, Xiaohui
Wong, Solomon S. Y.
Yin, Zheng
Roberts, Aaron W.
Nezamabadi, Aryan
Xu, Pingyi
Frost, Adaani
Jackson, Robert E.
Wong, Stephen T. C.
author_facet Wang, Lin
Li, Guihua
Ezeana, Chika F.
Ogunti, Richard
Puppala, Mamta
He, Tiancheng
Yu, Xiaohui
Wong, Solomon S. Y.
Yin, Zheng
Roberts, Aaron W.
Nezamabadi, Aryan
Xu, Pingyi
Frost, Adaani
Jackson, Robert E.
Wong, Stephen T. C.
author_sort Wang, Lin
collection PubMed
description Healthcare regulatory agencies have mandated a reduction in 30-day hospital readmission rates and have targeted COPD as a major contributor to 30-day readmissions. We aimed to develop and validate a simple tool deploying an artificial neural network (ANN) for early identification of COPD patients with high readmission risk. Using COPD patient data from eight hospitals within a large urban hospital system, four variables were identified, weighted and validated. These included the number of in-patient admissions in the previous 6 months, the number of medications administered on the first day, insurance status, and the Rothman Index on hospital day one. An ANN model was trained to provide a predictive algorithm and validated on an additional dataset from a separate time period. The model was implemented in a smartphone app (Re-Admit) incorporating four input risk factors, and a clinical care plan focused on high-risk readmission candidates was then implemented. Subsequent readmission data was analyzed to assess impact. The areas under the curve of receiver operating characteristics predicting readmission with ANN is 0.77, with sensitivity 0.75 and specificity 0.67 on the separate validation data. Readmission rates in the COPD high-risk subgroup after app and clinical intervention implementation saw a significant 48% decline. Our studies show the efficacy of ANN model on predicting readmission risks for COPD patients. The AI enabled Re-Admit smartphone app predicts readmission risk on day one of the patient’s admission, allowing for early implementation of medical, hospital, and community resources to optimize and improve clinical care pathways.
format Online
Article
Text
id pubmed-9712389
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-97123892022-12-02 An AI-driven clinical care pathway to reduce 30-day readmission for chronic obstructive pulmonary disease (COPD) patients Wang, Lin Li, Guihua Ezeana, Chika F. Ogunti, Richard Puppala, Mamta He, Tiancheng Yu, Xiaohui Wong, Solomon S. Y. Yin, Zheng Roberts, Aaron W. Nezamabadi, Aryan Xu, Pingyi Frost, Adaani Jackson, Robert E. Wong, Stephen T. C. Sci Rep Article Healthcare regulatory agencies have mandated a reduction in 30-day hospital readmission rates and have targeted COPD as a major contributor to 30-day readmissions. We aimed to develop and validate a simple tool deploying an artificial neural network (ANN) for early identification of COPD patients with high readmission risk. Using COPD patient data from eight hospitals within a large urban hospital system, four variables were identified, weighted and validated. These included the number of in-patient admissions in the previous 6 months, the number of medications administered on the first day, insurance status, and the Rothman Index on hospital day one. An ANN model was trained to provide a predictive algorithm and validated on an additional dataset from a separate time period. The model was implemented in a smartphone app (Re-Admit) incorporating four input risk factors, and a clinical care plan focused on high-risk readmission candidates was then implemented. Subsequent readmission data was analyzed to assess impact. The areas under the curve of receiver operating characteristics predicting readmission with ANN is 0.77, with sensitivity 0.75 and specificity 0.67 on the separate validation data. Readmission rates in the COPD high-risk subgroup after app and clinical intervention implementation saw a significant 48% decline. Our studies show the efficacy of ANN model on predicting readmission risks for COPD patients. The AI enabled Re-Admit smartphone app predicts readmission risk on day one of the patient’s admission, allowing for early implementation of medical, hospital, and community resources to optimize and improve clinical care pathways. Nature Publishing Group UK 2022-11-30 /pmc/articles/PMC9712389/ /pubmed/36450795 http://dx.doi.org/10.1038/s41598-022-22434-3 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Wang, Lin
Li, Guihua
Ezeana, Chika F.
Ogunti, Richard
Puppala, Mamta
He, Tiancheng
Yu, Xiaohui
Wong, Solomon S. Y.
Yin, Zheng
Roberts, Aaron W.
Nezamabadi, Aryan
Xu, Pingyi
Frost, Adaani
Jackson, Robert E.
Wong, Stephen T. C.
An AI-driven clinical care pathway to reduce 30-day readmission for chronic obstructive pulmonary disease (COPD) patients
title An AI-driven clinical care pathway to reduce 30-day readmission for chronic obstructive pulmonary disease (COPD) patients
title_full An AI-driven clinical care pathway to reduce 30-day readmission for chronic obstructive pulmonary disease (COPD) patients
title_fullStr An AI-driven clinical care pathway to reduce 30-day readmission for chronic obstructive pulmonary disease (COPD) patients
title_full_unstemmed An AI-driven clinical care pathway to reduce 30-day readmission for chronic obstructive pulmonary disease (COPD) patients
title_short An AI-driven clinical care pathway to reduce 30-day readmission for chronic obstructive pulmonary disease (COPD) patients
title_sort ai-driven clinical care pathway to reduce 30-day readmission for chronic obstructive pulmonary disease (copd) patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712389/
https://www.ncbi.nlm.nih.gov/pubmed/36450795
http://dx.doi.org/10.1038/s41598-022-22434-3
work_keys_str_mv AT wanglin anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT liguihua anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT ezeanachikaf anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT oguntirichard anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT puppalamamta anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT hetiancheng anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT yuxiaohui anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT wongsolomonsy anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT yinzheng anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT robertsaaronw anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT nezamabadiaryan anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT xupingyi anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT frostadaani anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT jacksonroberte anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT wongstephentc anaidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT wanglin aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT liguihua aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT ezeanachikaf aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT oguntirichard aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT puppalamamta aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT hetiancheng aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT yuxiaohui aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT wongsolomonsy aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT yinzheng aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT robertsaaronw aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT nezamabadiaryan aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT xupingyi aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT frostadaani aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT jacksonroberte aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients
AT wongstephentc aidrivenclinicalcarepathwaytoreduce30dayreadmissionforchronicobstructivepulmonarydiseasecopdpatients